Trevena, Inc. (NASDAQ:TRVN – Get Rating) – Investment analysts at HC Wainwright dropped their FY2022 earnings estimates for shares of Trevena in a report released on Tuesday, November 22nd. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($8.64) per share for the year, down from their previous forecast of ($8.25). The consensus estimate for Trevena’s current full-year earnings is ($8.67) per share. HC Wainwright also issued estimates for Trevena’s Q4 2022 earnings at ($1.73) EPS, Q1 2023 earnings at ($1.69) EPS, Q2 2023 earnings at ($0.96) EPS, Q3 2023 earnings at ($0.92) EPS, Q4 2023 earnings at ($0.89) EPS, FY2023 earnings at ($4.21) EPS, FY2024 earnings at ($1.62) EPS, FY2025 earnings at ($0.12) EPS and FY2026 earnings at $1.02 EPS.
Separately, StockNews.com started coverage on shares of Trevena in a research note on Wednesday. They issued a “sell” rating for the company.
Trevena Price Performance
Institutional Trading of Trevena
Several hedge funds and other institutional investors have recently bought and sold shares of TRVN. GSA Capital Partners LLP acquired a new position in shares of Trevena in the 1st quarter valued at approximately $471,000. Renaissance Technologies LLC raised its position in shares of Trevena by 90.8% in the 1st quarter. Renaissance Technologies LLC now owns 308,400 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 146,800 shares in the last quarter. Captrust Financial Advisors raised its position in shares of Trevena by 10,526.3% in the 1st quarter. Captrust Financial Advisors now owns 201,900 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 200,000 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its position in shares of Trevena by 133.3% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 65,858 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 37,633 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Trevena in the 2nd quarter valued at approximately $51,000. Institutional investors and hedge funds own 12.34% of the company’s stock.
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
- Get a free copy of the StockNews.com research report on Trevena (TRVN)
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.